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Report on Wage Structure. We also use other information such
as the Korean Statistical Information System. RESULTS: The
estimated costs of cancer are as follows: 9.60 billion US PPP$ ($
hereafter) in 1999, $9.60 billion in 2000, $9.62 billion in 2001,
$9.01 billion in 2002, and $9.87 billion in 2003. We ﬁnd that
indirect cost accounts for about 80% of total cost during that
period, but the proportion has been dropped since 2000; from
84.6% in 2000 to 78.7% in 2003. The proportions of the 
cost of male and female cancer patients are about 77% and 23%
respectively during the period. The cost of three major cancers
in 2003 accounts for 53.3% of total cost of cancers: the cost of
liver cancer is $2.26 billion (22.9% of total cost of all cancers);
$1.67 billion (16.9%) in stomach cancer; and $1.33 billion
(13.5%) in bronchial and lung cancer. CONCLUSIONS: The
cost of cancer has been steadily increasing from 1999~2003
except 2002, while the proportion of indirect costs has gradu-
ally decreased since 2000.
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OBJECTIVES: Poorly controlled CINV may lead to additional
ofﬁce or emergency room visits, thus, increasing the overall costs
of cancer care. This study estimates the societal costs of uncon-
trolled CINV for working-age cancer patients. METHODS:
Employees or spouse and/or dependents with cancer who
received highly or moderately emetogenic chemotherapy were
identiﬁed from a 1997–2002 proprietary dataset linking medical
claims to work-loss information. Patients were followed from the
earliest date of chemotherapy for up to six-months, excluding
those with less than three-months of continuous enrollment.
Direct medical costs were measured using payments, normalized
as monthly, and updated to 2004 USD. Work loss days were
identiﬁed from employment records. Costs of uncontrolled
CINV were derived by comparing medical costs and work-loss
days for three groups, patients with uncontrolled CINV and 
no ER visit, with uncontrolled CINV and ER visit, and with 
controlled CINV, using the Wilcoxon Mann-Whitney test in 
univariate analyses. All patients with uncontrolled CINV were
pooled as one group in multivariate analysis. RESULTS: In all,
2,071 patients were identiﬁed; 25% required medical care for
uncontrolled CINV; 2% had ER visits. Compared with patients
with controlled CINV ($8132), total direct costs were signiﬁ-
cantly higher for patients with uncontrolled CINV, no ER
($10,376, P < 0.001) and uncontrolled CINV and ER ($12,810,
P < 0.001), respectively. Estimated work-loss days were 6.1, 7.2,
and 8.9 days the above groups, respectively. After controlling 
for demographics, geographic regions, and comorbidities, the
difference in monthly medical costs between the controlled 
and uncontrolled group was $2619 (P < 0.001). However, the
difference in work-loss (0.21 days) was no longer signiﬁcant 
(P = 0.73). CONCLUSIONS: Uncontrolled CINV was associated
with a signiﬁcant increase in medical costs. For patients with
uncontrolled CINV but no ER visit, increases in cost were driven
by outpatient care, whereas for those with ER visits, inpatient
care was the major cost driver.
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OBJECTIVES: A variety of pharmacologic therapies are avail-
able or in development for the prevention of breast cancer recur-
rence. Assessing the beneﬁts of these treatments is compromised
by a paucity of data on the impact of recurrence on economic
costs and patient survival. The purpose of this study was to shed
light on these issues. METHODS: We conducted a retrospective
analysis of SEER-Medicare data, which consists of information
from the SEER cancer registry linked to administrative claims
from the Medicare program. All patients in SEER who were
diagnosed with and treated for primary breast cancer during
1991–1993 were identiﬁed, and their subsequent Medicare
claims histories were scanned for evidence of recurrence. Patients
were stratiﬁed according to type of recurrence (local, contralat-
eral, or distant) and their Medicare claims further scanned from
the time of their recurrence through 2002 to assess patterns of
survival and health care costs (which were inﬂated to 2003
dollars). Patients who did not have recurrence were used as con-
trols. Techniques pioneered by Lin for the analysis of censored
cost data were used to estimate ten-year undiscounted costs of
recurrence by type. RESULTS: We identiﬁed 8725 patients in
SEER who were diagnosed with and treated for primary breast
cancer during 1991–1993, including 1485 who subsequently 
had a recurrence (local, 759; contralateral, 228; distant, 498).
Median survival was 124.0 months among controls, versus 
42.8 and 7.1 months among patients with local and distant
recurrence, respectively; 52.4% of patients with contralateral
recurrence remained alive after all data were censored at 93.5
months. Cumulative ten-year costs following local, contralateral,
and distant breast cancer recurrence exceeded those of controls
by $84,406, $29,609, and $222,106, respectively. CONCLU-
SION: The impact of breast cancer recurrence on patient sur-
vival and economic costs is substantial and varies considerably
by type.
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OBJECTIVES: Both bicalutamide and ﬂutamide are commonly
used in combined androgen blockade (CAB) for prostate cancer.
Although bicalutamide is more costly than ﬂutamide, it is impor-
tant that efﬁcacy and quality of life outcomes as well as com-
pliance, and side effects are also taken into consideration when
determining whether CAB with bicalutamide is a cost-effective
option as compared to CAB with ﬂutamide. Unfortunately, there
have been no well-designed cost-effectiveness analyses compar-
ing bicalutamide vs. ﬂutamide as part of CAB. The goal of this
study was to determine the cost-effectiveness of CAB with bica-
lutamide vs. CAB with ﬂutamide in men with stage D2 prostate
cancer. METHODS: A decision model was created to compare
treatment strategies. Survival and side effect information was
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based on a randomized trial directly comparing bicalutamide 
and ﬂutamide. Costs and quality of life effects related to therapy
were based on published sources. Cost-effectiveness was calcu-
lated for 60 and 120 months from start of therapy. RESULTS:
The incremental cost per quality adjusted life year (QALY)
gained for bicalutamide vs. ﬂutamide was $22,000 and $16,000
per QALY at ﬁve and ten years, respectively. If quality adjust-
ment was not included, the incremental cost-effectiveness ratio
(ICER) for CAB with bicalutamide over CAB with ﬂutamide was
even more favorable ($20,000/LY gained at ﬁve years). These
ICER estimates are well within the commonly accepted cost-
effectiveness threshold. One way sensitivity analysis demon-
strated that the cost-effectiveness estimates were most sensitive
to drug costs and survival (baseline survival was not signiﬁcantly
different between therapies). Multi-way uncertainty analysis
revealed that the median value of the ICER at ﬁve years was
$13,637/QALY when all the parameters were varied over a clin-
ically reasonable range. CONCLUSIONS: Bicalutamide is cost-
effective compared with ﬂutamide when used for androgen
blockade as part of combined androgen blockade for men with
advanced prostate cancer.
PCN15
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OBJECTIVES: Bone metastases occur in up to 80% of advanced
prostate cancer patients, and could result in painful and debili-
tating skeletal complications. The objective of this study was to
evaluate resource utilization in advanced prostate cancer patients
with versus without bone pain. METHODS: A multi-center ret-
rospective chart review combined with prospective quality of 
life and pain assessment study was initiated to collect data 
from approximately 375 patients from 73 US community
urology practices. Patients were categorized as either with or
without bone pain. Interim analysis compared resource utiliza-
tion (hospitalizations, physicians visits) between the two groups,
using t-tests and Chi-square tests (p < 0.05) to assess differences.
RESULTS: Of 277 patients recruited to date, mean age was 76
years, and majority (74%) were Caucasian. About 39% (N =
109) had bone pain and the remaining 61% did not. Patients
with bone pain were signiﬁcantly younger than those without
(75 vs. 77 years) and more likely to have bone metastases (62%
vs. 40%). However, the groups did not differ signiﬁcantly in eth-
nicity, education, or comorbid conditions. Patients with bone
pain were over twice as likely to have been hospitalized in the
past year (28% vs. 13%) than those without and averaged 1.3
hospitalizations per patient and 4.2 days per stay. While outpa-
tient visit rates were similar, patients with bone pain were less
likely to make routine physician visits (42% versus 61%),
instead seeking treatment for non-routine reasons (e.g. LH-RH
agonist administration, initial/post-op consults, procedures/
surgery). Patients with bone pain were more likely to visit for
SRE (8% vs. 3%) and to receive a referral to oncology/urology
(6% vs. 3%) at physician visits. CONCLUSIONS: Patients with
bone pain have increased health resource consumption, particu-
larly hospitalizations, than patients without bone pain, which
may result in substantial economic burden.
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OBJECTIVE: Sepsis is a systemic inﬂammatory syndrome in
response to infection. Sepsis is considered severe when associated
with organ dysfunction, hypoperfusion, or hypotension. Severe
sepsis is considered the most common cause of death in non-
coronary critical care units. The impact of severe sepsis on the
oncology population has not been fully delineated. The objective
of this observational study is to describe the clinical outcomes
and direct medical costs of treating severe sepsis in the oncology
population at a comprehensive cancer center. METHODS: A
convenience sample of 20 intensive care unit patients diagnosed
with severe sepsis was followed prospectively during their severe
septic episode until death or hospital discharge. Clinical infor-
mation was obtained from the patient medical record. Resource
utilization and costs were retrieved from the institution’s ﬁnan-
cial database. RESULTS: The sample was 60% male with a mean
age of 63 years (27–82). The medical/surgical mix of patients
was 50/50. Sixty percent of patients had solid tumors and 40%
had hematological malignancies. Four patients were neutropenic
on ICU admission. Eighty percent of patients had an APACHE
II score ≥25 on admission to the ICU. The majority of patients
required vasopressor support (95%) and mechanical ventilation
(85%). Eight patients (40%) required dialysis and seven patients
(35%) received drotrecogin alfa. The lung was the most common
presumed infection source. The mean length of stay in the ICU
was 16 days (1–41). Survivors constituted 25% of the group.
The top cost drivers for physician services included: 1) intensive
care unit; 2) nephrology; and 3) radiology and for hospital care
included: 1) room and board; 2) pharmacy; and 3) respiratory
care. A detailed cost analysis is ongoing. CONCLUSION: The
clinical outcomes of oncology patients who develop severe sepsis
are poor despite intensive therapeutic intervention and resultant
high resource utilization and costs.
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OBJECTIVE: To determine breast cancer knowledge, screening
behavior, perceived risk, and willingness to consume chemopre-
ventive agent and their interrelationships in West Virginia 
Medicaid Program (WVMP) women enrollees. METHODS: A
survey of randomly selected women >40 years of age who were
enrollees of WVMP was conducted. The questionnaire collected
information on following components: utilization of breast
cancer preventive strategies, perceived and actual (as calculated
by Gail model) risk of breast cancer, breast cancer knowledge,
and willingness to consume chemopreventive agents. RESULTS:
A total of 606 responses were obtained from a reachable sample
size of 1502, yielding a response rate of 40.4%. Non–response
bias assessment indicated minimal potential for non-response
bias. Only 50.7% of respondents were compliant with the 
American Cancer Society screening guidelines. Almost none of
the respondent (96.7%) had ever taken chemopreventive tamox-
ifen. A large proportion of respondents were not sure about their
